Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257395 | 0.93 | PTGS2 (0.46) | P2RY1RXRANR1H2NR1H3KLKB1 | |
| SCHEMBL12361445 | 0.92 | SMN1; SMN2 (0.44) | P2RY1RXRANR1H2NR1H3KLKB1 | |
| SCHEMBL2260114 | 0.89 | RXRA (0.49) | RXRANR1H2NR1H3MAPTTGFBR1 | |
| SCHEMBL2259001 | 0.89 | NR4A2 (0.46) | RXRANR1H2NR1H3TRPV1 | |
| SCHEMBL2256859 | 0.87 | CYP2C9 (0.46) | RXRANR1H2NR1H3CNR1SMN1; SMN2 | |
| SCHEMBL2257146 | 0.86 | MAOB (0.47) | RXRANR1H2NR1H3MAPTTGFBR1 | |
| SCHEMBL2258160 | 0.85 | RXRA (0.44) | RXRANR1H2NR1H3CNR1MAPT | |
| SCHEMBL2257772 | 0.84 | RXRA (0.43) | RXRANR1H2NR1H3MAPTTGFBR1 | |
| SCHEMBL2258478 | 0.84 | RXRA (0.43) | RXRANR1H2NR1H3MAPTTGFBR1 | |
| SCHEMBL2256763 | 0.84 | NR4A2 (0.40) | RXRANR1H2NR1H3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2121621-A1 | LXR AND FXR MODULATORS | Exelixis, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | P2RY1 302/4885RXRA 8/4885NR1H2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.